3D Printing Direct Powder Extrusion in the Production of Drug Delivery Systems: State of the Art and Future Perspectives
Pharmaceutics,
Год журнала:
2024,
Номер
16(4), С. 437 - 437
Опубликована: Март 22, 2024
The
production
of
tailored,
on-demand
drug
delivery
systems
has
gained
attention
in
pharmaceutical
development
over
the
last
few
years,
thanks
to
application
3D
printing
technology
field.
Recently,
direct
powder
extrusion
(DPE)
emerged
among
extrusion-based
additive
manufacturing
techniques.
It
is
a
one-step
procedure
that
allows
processing
powdered
formulations.
aim
this
systematic
literature
review
analyze
using
DPE.
A
total
27
articles
have
been
identified
through
scientific
databases
(Scopus,
PubMed,
and
ScienceDirect).
main
characteristics
three
types
printers
based
on
DPE
discussed.
selection
polymers
auxiliary
excipients,
as
well
flowability
mixture,
rheological
properties
molten
material,
temperatures
critical
parameters
for
successful
printing.
wide
range
with
varied
geometries
different
release
profiles
intended
oral,
buccal,
parenteral,
transdermal
routes
produced.
ability
technique
manufacture
personalized,
proven.
For
all
these
reasons,
its
implementation
hospital
settings
near
future
seems
promising.
Язык: Английский
3D printing of pharmaceutical dosage forms: Recent advances and applications
Auel Tobias,
Mentrup Aaron Felix Christofer,
Olivier Roy
и другие.
Advanced Drug Delivery Reviews,
Год журнала:
2024,
Номер
unknown, С. 115504 - 115504
Опубликована: Дек. 1, 2024
Язык: Английский
Pharmaceutical 3D Printing Technology Integrating Nanomaterials and Nanodevices for Precision Neurological Therapies
Pharmaceutics,
Год журнала:
2025,
Номер
17(3), С. 352 - 352
Опубликована: Март 9, 2025
Pharmaceutical
3D
printing,
combined
with
nanomaterials
and
nanodevices,
presents
a
transformative
approach
to
precision
medicine
for
treating
neurological
diseases.
This
technology
enables
the
creation
of
tailored
dosage
forms
controlled
release
profiles,
enhancing
drug
delivery
across
blood−brain
barrier
(BBB).
The
integration
nanoparticles,
such
as
poly
lactic-co-glycolic
acid
(PLGA),
chitosan,
metallic
nanomaterials,
into
3D-printed
scaffolds
improves
treatment
efficacy
by
providing
targeted
prolonged
release.
Recent
advances
have
demonstrated
potential
these
systems
in
conditions
like
Parkinson’s
disease,
epilepsy,
brain
tumors.
Moreover,
printing
allows
multi-drug
combinations
personalized
formulations
that
adapt
individual
patient
needs.
Novel
approaches,
including
stimuli-responsive
systems,
on-demand
dosing,
theragnostics,
provide
new
possibilities
real-time
monitoring
disorders.
Despite
innovations,
challenges
remain
terms
scalability,
regulatory
approval,
long-term
safety.
future
perspectives
this
suggest
its
revolutionize
treatments
offering
patient-specific
therapies,
improved
penetration,
enhanced
outcomes.
review
discusses
current
state,
applications,
nanotechnology
treatment,
highlighting
need
further
research
overcome
existing
challenges.
Язык: Английский
The Future of Medicine: How 3D Printing Is Transforming Pharmaceuticals
Pharmaceutics,
Год журнала:
2025,
Номер
17(3), С. 390 - 390
Опубликована: Март 19, 2025
Three-dimensional
printing
technology
is
transforming
pharmaceutical
manufacturing
by
shifting
from
conventional
mass
production
to
additive
manufacturing,
with
a
strong
emphasis
on
personalized
medicine.
The
integration
of
bioinks
and
AI-driven
optimization
further
enhancing
this
innovation,
enabling
drug
precise
dosages,
tailored
drug-release
profiles,
unique
multi-drug
combinations
that
respond
individual
patient
needs.
This
advancement
significantly
impacting
healthcare
accelerating
development,
encouraging
innovative
designs,
treatment
efficacy.
Traditional
follows
one-size-fits-all
approach,
which
often
fails
meet
the
specific
requirements
patients
medical
conditions.
In
contrast,
3D
printing,
coupled
bioink
formulations,
allows
for
on-demand
production,
reducing
dependency
large-scale
storage.
AI-powered
design
process
refine
dosage
forms,
printability,
release
mechanisms,
ensuring
precision
efficiency
in
manufacturing.
These
advancements
have
potential
lower
overall
costs
while
improving
adherence
medication
regimens.
review
explores
potential,
challenges,
environmental
benefits
positioning
it
as
key
driver
next-generation
Язык: Английский
Sex-specific formulations of doxazosin mesylate via direct powder extrusion 3D printing
Drug Delivery and Translational Research,
Год журнала:
2025,
Номер
unknown
Опубликована: Апрель 22, 2025
Abstract
Males
and
females
are
known
to
exhibit
significant
differences
in
drug
pharmacokinetics
pharmacodynamics,
which
still
overlooked
pharmaceutical
research
development.
These
disparities
contribute
adverse
effects
increased
mortality
females,
highlighting
the
critical
need
for
sex-specific
formulations.
Extended-release
formulations
of
doxazosin
mesylate,
an
alpha
blocker
used
treat
hypertension,
have
shown
sex-based
pharmacokinetics,
leading
heightened
rendering
current
titration
recommendations
impractical.
This
study
explored
potential
a
3D
printing
(3DP)
technology,
direct
powder
extrusion
(DPE),
producing
personalised,
doses
mesylate.
A
simple
three
component
formulation
was
made
composed
hydroxypropyl
cellulose
(HPC)
polymer
Klucel
JF,
D-mannitol,
printlets
varying
(1,
2,
3
mg)
were
manufactured
from
single
1%
w/w
pharma-ink
batch,
enabling
easy
dose
personalisation
by
adjusting
printlet
dimensions.
The
use
supports
technology’s
ease
pharmacy
setting,
eliminating
frequent
changes
during
compounding
process.
In
vitro
dissolution
testing
revealed
extended
release
profile,
influenced
surface-area-to-volume
(SA:
V)
ratios.
Introducing
channels
larger
standardized
SA:
V
ratios,
enhancing
profile
uniformity.
Release
kinetics
followed
Hixson-Crowell
Korsmeyer-Peppas
models,
indicating
diffusion
swelling
mechanisms.
work
highlights
capability
DPE
3DP
creating
personalized,
extended-release
oral
dosage
forms,
supporting
precise
customization
patient-specific
therapy.
Язык: Английский
Expediting 3D printed medication development using vacuum compression moulding
Anna Kirstine Jørgensen,
Ye Chan Oh,
Hanxiang Li
и другие.
Journal of Controlled Release,
Год журнала:
2025,
Номер
unknown, С. 113766 - 113766
Опубликована: Апрель 1, 2025
Язык: Английский
Application of 3D printing on the design and development of pharmaceutical oral dosage forms
Journal of Controlled Release,
Год журнала:
2024,
Номер
373, С. 463 - 480
Опубликована: Июль 25, 2024
3D
printing
technologies
confer
an
unparalleled
degree
of
control
over
the
material
distribution
on
structures
they
produce,
which
has
led
them
to
become
extremely
attractive
research
topic
in
pharmaceutical
dosage
form
development,
especially
for
design
personalized
treatments.
With
fine
tuning
selection
and
careful
design,
these
allow
tailor
not
only
amount
drug
administered
but
biopharmaceutical
behaviour
forms
as
well.
While
fused
deposition
modelling
(FDM)
is
still
most
studied
technology
this
area,
others
are
gaining
more
relevance,
many
new
exciting
developed
during
2022
2023.
Considering
that
technologies,
time,
will
join
current
manufacturing
methods
with
ever-increasing
knowledge
topic,
our
review
aims
explore
advantages
limitations
employed
development
oral
forms,
giving
special
focus
important
aspects
governing
resulting
release
profiles.
Язык: Английский
Single-Step Extrusion Process for Formulation Development of Self-Emulsifying Granules for Oral Delivery of a BCS Class IV Drug
Molecular Pharmaceutics,
Год журнала:
2024,
Номер
unknown
Опубликована: Окт. 8, 2024
This
study
aimed
to
develop
and
optimize
formulations
containinga
BCS
Class
IV
drug
by
improving
its
solubility
permeability.
Herein
development
of
self-emulsifying
solid
lipid
matrices
was
investigated
as
carrier
systems
for
a
model
drug.
Self-emulsifying
delivery
(SEDDS)
have
been
extensively
formulating
drugs
with
poor
water
solubility.
However,
manufacturing
SEDDS
is
challenging.
These
usually
low
drug-loading
capacities,
the
incorporated
tend
recrystallize
during
storage,
which
severely
impacts
storage
stability
in
vitro
performance
vivo.
Moreover,
they
require
greater
amounts
(>80%)
carriers,
cosolvents,
surfactants,
other
excipients
keep
them
from
recrystallizing.
turn
again
challenging
high-dose
it
affects
size
final
product
(tablets
capsules).
Also,
liquid
nature
formulation
handling
processability
formulation,
poses
challenges
packaging
steps.
In
this
work,
we
studied
feasibility
single-step
extrusion
process
formulate
granules
relatively
higher
loading
Ritonavir
(RTV),
Further,
compared
using
these
feedstock
direct
powder
extrusion-based
3D
printing
opposed
use
physical
blends.
The
solubility-permeability
advantage
also
evaluated
where
showed
about
27
20
fold
increase
apparent
solublity
permeability
bulk
drug,
respectively.
Combining
capabilities
HME
form
drug-loaded
homogeneous
continuous
along
application
extruiosn
(DPE)
improves
prospects
such
candidates.
Язык: Английский
Twin Screw Melt Granulation of Simvastatin: Drug Solubility and Dissolution Rate Enhancement Using Polymer Blends
Pharmaceutics,
Год журнала:
2024,
Номер
16(12), С. 1630 - 1630
Опубликована: Дек. 23, 2024
Background/Objectives:
This
study
evaluates
the
efficacy
of
twin
screw
melt
granulation
(TSMG),
and
hot-melt
extrusion
(HME)
techniques
in
enhancing
solubility
dissolution
simvastatin
(SIM),
a
poorly
water-soluble
drug
with
low
bioavailability.
Additionally,
explores
impact
binary
polymer
blends
on
drug’s
miscibility,
solubility,
vitro
release
profile.
Methods:
SIM
was
processed
various
polymeric
combinations
at
30%
w/w
load,
1:1
ratio
blends,
including
Soluplus®
(SOP),
Kollidon®
K12
(K12),
VA64
(KVA),
Kollicoat®
IR
(KIR).
The
solid
dispersions
were
characterized
using
modulated
differential
scanning
calorimetry
(M-DSC),
powder
X-ray
diffraction
(PXRD),
Fourier-transform
infrared
spectroscopy
(FTIR).
Dissolution
studies
compared
developed
formulations
against
marketed
product.
Results:
SIM-SOP/KIR
blend
showed
highest
(34
µg/mL),
achieving
an
approximately
5.5-fold
enhancement
over
pure
drug.
that
had
significantly
higher
profiles
than
physical
mixture
(PM)
(p
<
0.01).
their
similar
to
formulation,
100%
within
30
min.
In
contrast,
SIM-K12/KIR
formulation
exhibited
strong
but
limited
slower
rates,
suggesting
high
miscibility
does
not
necessarily
correlate
improved
solubility.
Conclusions:
demonstrates
effectiveness
TSMG,
HME
as
effective
continuous
manufacturing
technologies
for
improving
therapeutic
drugs.
It
also
emphasizes
complexity
polymer–drug
interactions
necessity
carefully
selecting
compatible
polymers
optimize
quality
performance
pharmaceutical
formulations.
Язык: Английский
Optimising 3D printed medications for rare diseases: In-line mass uniformity testing in direct powder extrusion 3D printing
International Journal of Pharmaceutics,
Год журнала:
2024,
Номер
668, С. 124964 - 124964
Опубликована: Ноя. 16, 2024
Biotinidase
deficiency
is
a
rare
inherited
disorder
characterized
by
biotin
metabolism
issues,
leading
to
neurological
and
cutaneous
symptoms
that
can
be
alleviated
through
administration.
Three-dimensional
(3D)
printing
(3DP)
offers
potential
for
personalized
medicine
production
diseases,
due
its
flexibility
in
designing
dosage
forms
controlling
release
profiles.
For
such
point-of-care
applications,
rigorous
quality
control
(QC)
measures
are
essential
ensure
precise
dosing,
optimal
performance,
product
safety,
especially
low
doses
preclinical
clinical
studies.
In
this
work,
we
addressed
QC
challenges
integrating
precision
balance
into
direct
powder
extrusion
pharmaceutical
3D
printer
(M3DIMAKER™)
real-time,
in-line
mass
uniformity
testing,
critical
step.
Small
large
capsule-shaped
printlets
(3D
printed
tablets)
immediate-
extended-release
were
printed.
The
integrated
monitored
registered
each
printlet's
weight,
identifying
any
deviations
from
acceptable
limits.
While
all
printlet
batches
met
criteria,
some
small
exhibited
weight
deviations.
vitro
studies
showed
immediate-release
releasing
82%
of
within
45
min,
compared
100%
printlets.
formulations,
35%
the
drug
was
released
printlets,
whereas
24%
at
same
time
point.
integration
process
analytical
technology
tools
3DP
shows
promise
enhancing
scalability
dosing
point-of-care,
demonstrating
successful
testing
across
different
sizes
Язык: Английский